Coronavirus (COVID-19) Collection
Endotheliopathy marked by high von Willebrand factor (vWF) antigen in COVID-19 is associated with poor outcome: a systematic review and meta-analysisCoronavirus disease 2019 (COVID-19) is currently one of the most common diseases in the world, and has a considerable death toll (WHO, 2021). Although most patients have mild–moderate clinical manifestations, a significant proportion of patients develop life-threatening complications (Lim et al., 2020; Pranata et al., 2020a, 2021c). Complications caused by coagulopathy are among the most important. Activation of the coagulation pathway and endothelial cells (ECs) is a hallmark of severe COVID-19, which is consistent with high rates of venous thromboembolism (VTE), pulmonary embolism (PE) and disseminated intravascular coagulation (DIC) (Mancini et al., 2021a; Ward et al., 2021).
Third wave of COVID-19 in Madrid, SpainMadrid has been the epicenter of COVID-19 in Spain, primarily due to its high population density and mobility. The city has 3.3 million people, with 6.8 million across the metropolitan area. Up to March 15 2021, roughly 605 000 persons had been diagnosed with SARS-CoV-2 infection and 14 000 had died in the Madrid region (Ministerio de Sanidad, 2021; Instituto Nacional de Estadística, 2021). These figures refer to laboratory-confirmed cases, which underestimate the true number as testing access was limited during the earlier stages of the pandemic (Soriano and Barreiro, 2020).
Comparative assessment of mortality risk factors between admission and follow-up models among patients hospitalized with COVID-19The SARS-CoV-2 virus has infected more than 100 million and killed nearly 2.5 million people worldwide over the past few months (JHU, 2020). Although most patients are asymptomatic or have mild symptoms, 10% of them require hospitalization and 5% advanced medical support (Wu and McGoogan, 2020). Early identification of severe cases that will demand longer hospitalizations and increased costs can help guide medical decisions and manage hospital resources, especially in economically deprived areas.
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19As of May 27, 2020, there were over 1,678,843 confirmed cases of COVID-19 claiming more than 100,000 lives in the Unites States (CDC, 2020). Currently there is no known effective therapy or vaccine. The urgent need for therapeutic agents has resulted in repurposing and redeployment of experimental agents (McCreary and Pogue, 2020; Sanders et al., 2020).